Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

2020367 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 21, Issue 10, pp. 1283-1295

Field-Weighted Citation Impact: 18.43